Articles From: Ipsen and the Salk Institute renew their agreement for discovery research in medical sciences to IRADIMED CORPORATION Announces Receipt of FDA Warning Letter


2014/11/18
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) and the Salk Institute for Biological Studies (Salk Institute) today announced that they have agreed to renew their collaboration in medical sciences for another three years.
Sign-up for Ipsen and the Salk Institute renew their agreement for discovery research in medical sciences investment picks
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for Dysport ® (abobotulinumtoxinA) in the treatment of upper limb spasticity in adult patients.
Sign-up for Ipsen Announces FDA Acceptance of Filing for Dysport® in the Treatment of Upper Limb Spasticity in Adult Patients investment picks
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that the U.S. Food and Drug Administration (FDA) has approved a new device to deliver Somatuline ® Depot ® (lanreotide). The device has an enhanced, prefilled, low-volume syringe that supports full-dose delivery with no reconstitution requirements.
Sign-up for Ipsen Announces FDA Approval of a New Delivery Device for Somatuline® Depot® (lanreotide) Injection investment picks
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced positive results from the phase III study of triptorelin pamoate 11.25 mg (Decapeptyl ® 3 months) administered subcutaneously in patients with locally advanced or metastatic prostate cancer at the European Association of Urology (EAU) 14 th Central European Meeting in Cracow, Poland (10-12 October 2014). The primary objective of the study was to assess the efficacy and safety profile of the sustained-release triptorelin pamoate 11.25 mg (Decapeptyl ® 3 months) formulation when administered by the subcutaneous route in men with locally advanced or metastatic prostate cancer.
Sign-up for Ipsen Announces Positive Results from Phase III Clinical Study of Decapeptyl® (triptorelin pamoate) 11.25 mg Administered by Subcutaneous Route to Prostate Cancer Patients investment picks
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the International Breast Cancer Study Group (IBCSG) presented results of the randomized phase III SOFT clinical trial at the 2014 San Antonio Breast Cancer Symposium.
Sign-up for Ipsen Announces That the International Breast Cancer Study Group (IBCSG) Presented Phase 3 Results Evaluating the Use of Ovarian Suppression to Adjuvant Treatment with Tamoxifen investment picks
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext:IPN; ADR:IPSEY), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for Dysport ® (abobotulinumtoxinA) for the treatment of upper limb spasticity in adult patients.
Sign-up for Ipsen Biopharmaceuticals, Inc. Announces FDA Acceptance of Filing for Dysport® (abobotulinumtoxinA) in the Treatment of Upper Limb Spasticity in Adult Patients investment picks
2014/11/5
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that Donald Pearl has joined the company as Vice President of Neurology.
Sign-up for Ipsen Biopharmaceuticals, Inc. Announces Hire of Donald Pearl as Vice President of Neurology investment picks
2014/11/24
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY) today announced the implementation of IPSEN CARES TM (Coverage, Access, Reimbursement, & Education Support). Ensuring patients, providers and caregivers have the resources needed to help access the Ipsen medications that are critical to managing their conditions, IPSEN CARES is staffed Monday to Friday by experts who can assist with a broad range of medical, educational, logistical and coverage information regarding Ipsen medicines, including Increlex ® (mecasermin), Somatuline ® Depot ® (lanreotide), and Dysport ® (abobotulinumtoxinA). “At Ipsen, improving the lives of patients is what drives us each and every day,” said Cynthia Schwalm, President and CEO , Ipsen N.A. “We are committed to providing information and support to our patients to help them access,
Sign-up for Ipsen Biopharmaceuticals, Inc. Announces IPSEN CARES™, An Enhanced Patient Support Program investment picks
2014/9/27
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation at the ESMO 2014 Congress (26-30 September in Madrid) of the preliminary results of the phase II proof-of-concept clinical trial with tasquinimod in monotherapy, evaluating the compound in four advanced tumor types.
Sign-up for Ipsen Presents Preliminary Results of Exploratory Proof-of-Concept Study with Tasquinimod in Four Advanced Tumor Types at the ESMO 2014 Congress investment picks
2014/10/29
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today reported its sales for the third quarter and first nine months of 2014.
Sign-up for Ipsen: sales in the 3rd quarter and first nine months of 2014 investment picks
Leading Companies, Universities and Laboratories Sponsor Pooled ULR Contract on IEEE 802.11n CHICAGO , Oct.
Sign-up for IPXI® Announces Multi-Party Offering for Wireless Communications Standard Essential Patents investment picks
Schubert Jonckheer & Kolbe LLP Investigates Case Against the Company's Top Executives SAN FRANCISCO , Oct.
Sign-up for IPXL Shareholder Alert: Do You Own Stock in IPXL Educational Services? investment picks
International Rectifier, IR ® (NYSE: IRF), a world leader in power management technology, today announced the expansion of its portfolio of insulated-gate bipolar transistors (IGBTs) with the introduction of a family of rugged, reliable 650V devices optimized for fast switching applications including solar inverters, welding equipment, industrial motors, induction heating and uninterruptible power supplies (UPS). Ranging from 15A to 90A, the IRGP47xx family of IGBTs utilizes trench thin-wafer technology to reduce conduction and switching losses to deliver increased system efficiency.
Sign-up for IR Expands Portfolio of Ultra-fast Trench IGBTs with 650V Devices for Welding, Solar, Industrial Motors, Induction Heating and UPS Applications investment picks
International Rectifier, IR ® (NYSE: IRF), a world leader in power management technology, today announced the expansion of its StrongIRFET™ MOSFET portfolio to include 75V devices for a wide variety of industrial applications including power tools, Light Electric Vehicle (LEV) inverters, DC motor drives, Li-Ion battery pack protection, Hot-Swap and Switched Mode Power Supply (SMPS) secondary-side synchronous rectification.
Sign-up for IR Expands StrongIRFET™ Family with New 75V MOSFETs Featuring Ultra-low Rds(on) for Industrial Applications investment picks
International Rectifier, IR ® (NYSE: IRF), a world leader in power management technology, today announced the expansion of its StrongIRFET™ MOSFET portfolio to include 75V devices for a wide variety of industrial applications including power tools, Light Electric Vehicle (LEV) inverters, DC motor drives, Li-Ion battery pack protection, Hot-Swap and Switched Mode Power Supply (SMPS) secondary-side synchronous rectification.
Sign-up for IR Expands StrongIRFET™ Family with New Surface Mount 75V MOSFETs Featuring Ultra-low Rds(on) for Industrial Applications investment picks
International Rectifier, IR ® (NYSE: IRF), a world leader in power management technology, today introduced a comprehensive family of IGBT modules for high power industrial applications including motor drive inverters, switch mode power supplies (SMPS), uninterruptible power supplies (UPS), solar inverters and welding.
Sign-up for IR Introduces New Family of IGBT Modules for High Power Industrial Applications investment picks
International Rectifier, IR ® (NYSE: IRF), a world leader in power management technology, today announced the introduction of the AUIRGP66524D0 and AUIRGF66524D0 automotive-qualified 600V IGBTs optimized for small auxiliary motor drive applications including air conditioning compressors for electric and hybrid vehicles.
Sign-up for IR Introduces Rugged AUIRGP66524D0 and AUIRGF66524D0 Automotive-Qualified 600V IGBTs for Hybrid and Electric Vehicles investment picks
International Rectifier , IR ® (NYSE: IRF), a world leader in power management technology, today announced the company's CHiL ® Digital PWM Controllers and Integrated PowIRstage ® solution has been named a Top 10 Power Product of 2014 by Electronic Products China (EPC). EPC’s editors and panel of experts determine the top power products based on criteria that includes a significant advancement in a technology or its application, innovative design, and substantial achievement in price/performance. IR’s new digital controllers meet Intel VR12 and VR12.5 specifications, and support multiphase designs from 1 to 8 phases operating 1 to 2 loops.
Sign-up for IR's CHiL® Digital PWM Controller and Integrated PowIRStage® Named a Top 10 Power Product by Electronic Products China investment picks
International Rectifier, IR ® (NYSE: IRF), a world leader in power management technology, today introduced a new generation Insulated Gate Bipolar Transistor (IGBT) technology platform.
Sign-up for IR’s 1200V Gen8 IGBT Family Delivers Benchmark Efficiency and Ruggedness for Industrial Applications investment picks
International Rectifier, IR ® (NYSE: IRF), a world leader in power management technology, today announced the introduction of the IRFH4257D FastIRFET™ dual power MOSFET housed in a high performance 4x5 PQFN power block package.
Sign-up for IR’s 25V IRFH4257D FastIRFET™ in 4x5 PQFN Power Block Package Offers High Density, Compact Solution for DC-DC Applications investment picks
International Rectifier, IR ® (NYSE: IRF), a world leader in power management technology, today announced the introduction of the AUIRFN8459 and AUIRFN8458 40V automotive-qualified COOLiRFET™ power MOSFETs that offer benchmark on-state resistance (RDS(on)) for automotive applications requiring compact size and high current performance including pump motor control and automotive body control.
Sign-up for IR’s Automotive-Qualified 40V 5x6mm Dual PQFN COOLiRFET™s Deliver Benchmark Performance for Low Power Motor Applications investment picks
International Rectifier, IR ® (NYSE: IRF), a world leader in power management technology, today announced the introduction of an extensive portfolio of devices featuring IR’s latest low-voltage MOSFET silicon for lithium-ion battery protection applications including the IRL6297SD dual N-channel DirectFET ® MOSFET .
Sign-up for IR’s Family of Battery Protection MOSFETs Offers Cost-Effective, Flexible Solution for Mobile Applications investment picks
International Rectifier, IR ® (NYSE: IRF), a world leader in power management technology, today announced the introduction of IR’s µHVIC™ family of general purpose high-voltage and low-voltage integrated circuits that simplifies power system development by offering easy-to-implement building blocks for frequently used circuit elements.
Sign-up for IR’s µHVIC™ Family of Easy-to-Implement Building Blocks Simplifies Design investment picks
2010/02/22
The best and worst candidates for this maneuver, and details on how it works.
Sign-up for IRA Conversion Fact Sheet investment picks
2011/02/15
We highlight the best and worst candidates for this maneuver, and details on how it works.
Sign-up for IRA Conversion Fact Sheet investment picks
2009/08/27
Low investment balances, relaxed income limits make it worthy of consideration.
Sign-up for IRA Conversion: The Planning Opportunity of the Decade? investment picks
WINTER SPRINGS, Fla., Sept.
Sign-up for IRADIMED CORPORATION Announces Conference Call to Discuss the Status of the Recent FDA Warning Letter investment picks
WINTER SPRINGS, Fla., Sept.
Sign-up for IRADIMED CORPORATION Announces Receipt of FDA Warning Letter investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Ipsen and the Salk Institute renew their agreement for discovery research in medical sciences to IRADIMED CORPORATION Announces Receipt of FDA Warning Letter
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent